Walleye Trading LLC - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 174 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.4%.

Quarter-by-quarter ownership
Walleye Trading LLC ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q3 2023$120,246
-61.2%
122,700
-45.0%
0.00%
-100.0%
Q2 2023$310,248
-35.8%
223,200
-26.5%
0.00%0.0%
Q1 2023$482,883
-76.2%
303,700
-6.6%
0.00%
-83.3%
Q4 2022$2,025,373
-15.7%
325,100
-9.3%
0.01%
-14.3%
Q3 2022$2,402,000
+57.2%
358,570
+49.2%
0.01%
+40.0%
Q2 2022$1,528,000
+232.9%
240,300
+143.0%
0.01%
+400.0%
Q1 2022$459,000
-75.6%
98,900
-73.7%
0.00%
-85.7%
Q4 2021$1,882,000
-52.3%
376,249
+14.8%
0.01%
-50.0%
Q3 2021$3,948,000
+729.4%
327,724
+1356.6%
0.01%
+600.0%
Q2 2021$476,000
-34.8%
22,500
-13.5%
0.00%
-33.3%
Q1 2021$730,000
-4.1%
26,000
-11.3%
0.00%0.0%
Q4 2020$761,000
-4.4%
29,300
+89.0%
0.00%
-40.0%
Q2 2020$796,000
+108.4%
15,500
+28.1%
0.01%
+66.7%
Q1 2020$382,000
-68.9%
12,100
-41.3%
0.00%
-66.7%
Q4 2019$1,229,000
+110.8%
20,600
+29.6%
0.01%
+80.0%
Q3 2019$583,000
+4.5%
15,900
+32.7%
0.01%0.0%
Q2 2019$558,000
-60.8%
11,986
-66.2%
0.01%
-50.0%
Q1 2019$1,425,000
-36.3%
35,497
-27.0%
0.01%
-41.2%
Q4 2018$2,236,000
+704.3%
48,602
+584.5%
0.02%
+1600.0%
Q2 2018$278,0007,1000.00%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q4 2019
NameSharesValueWeighting ↓
Meditor Group Ltd 4,468,835$27,840,84218.82%
Ikarian Capital, LLC 1,891,147$11,781,8462.84%
Altium Capital Management LP 620,000$3,862,6001.96%
Ikarian Capital, LLC 1,296,900$8,079,6871.95%
Parkman Healthcare Partners LLC 822,784$5,125,9441.36%
Deep Track Capital, LP 4,000,000$24,920,0001.05%
Monaco Asset Management SAM 470,100$2,928,7230.88%
BRAIDWELL LP 3,393,405$21,140,9130.71%
Telemetry Investments, L.L.C. 71,000$4420.70%
Rhenman & Partners Asset Management AB 900,000$5,607,0000.58%
View complete list of ESPERION THERAPEUTICS INC NE shareholders